Breaking Ground In Prevention & Relief Of Anxiety & PTSD: Silo Pharma' Nasal Formulation For Ketamine-Based Treatment
Portfolio Pulse from Lara Goldstein
Silo Pharma (NASDAQ:SILO) has advanced the formulation development for its ketamine-composed drug SPC-15, intended for the treatment and prevention of anxiety, PTSD and other stress-related disorders. The feasibility study assessing SPC-15’s dose strengths has shown positive linearity, accuracy, and repeatability. The company is currently in discussions with potential delivery partners. The feasibility data could be used for upcoming studies related to the company’s SPC-14 therapeutic targeting Alzheimer’s.
August 08, 2023 | 8:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Silo Pharma has made significant progress in the development of its ketamine-based drug SPC-15. Positive results from the feasibility study and potential implications for Alzheimer's treatment could positively impact the company's stock.
The news of Silo Pharma's progress in the development of its ketamine-based drug SPC-15 is directly related to the company's core business. The positive results from the feasibility study and the potential implications for Alzheimer's treatment could attract investor interest and drive the company's stock price up in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100